Weiss HL - Search Results

1

Bayesian monitoring of phase II trials in cancer chemoprevention.

Cronin KA, Freedman LS, Lieberman R, Weiss HL, Beenken SW, Kelloff GJ. Cronin KA, et al. Among authors: weiss hl. J Clin Epidemiol. 1999 Aug;52(8):705-11. doi: 10.1016/s0895-4356(99)00063-3. J Clin Epidemiol. 1999. PMID: 10465313

2

Bayesian monitoring of a phase 2 chemoprevention trial in high-risk cohorts for prostate cancer.

Weiss HL, Urban DA, Grizzle WE, Cronin KA, Freedman LS, Kelloff GJ, Lieberman R. Weiss HL, et al. Urology. 2001 Apr;57(4 Suppl 1):220-3. doi: 10.1016/s0090-4295(00)00979-1. Urology. 2001. PMID: 11295632 Clinical Trial.

3

Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53.

Beenken SW, Grizzle WE, Crowe DR, Conner MG, Weiss HL, Sellers MT, Krontiras H, Urist MM, Bland KI. Beenken SW, et al. Among authors: weiss hl. Ann Surg. 2001 May;233(5):630-8. doi: 10.1097/00000658-200105000-00006. Ann Surg. 2001. PMID: 11323501 Free PMC article. Clinical Trial.

4

Evaluation of biomarker modulation by fenretinide in prostate cancer patients.

Urban D, Myers R, Manne U, Weiss H, Mohler J, Perkins D, Markiewicz M, Lieberman R, Kelloff G, Marshall M, Grizzle W. Urban D, et al. Eur Urol. 1999;35(5-6):429-38. doi: 10.1159/000019875. Eur Urol. 1999. PMID: 10325501 Clinical Trial.

5

Extent of surgery for intermediate-risk well-differentiated thyroid cancer.

Beenken S, Roye D, Weiss H, Sellers M, Urist M, Diethelm A, Goepfert H. Beenken S, et al. Am J Surg. 2000 Jan;179(1):51-6. doi: 10.1016/s0002-9610(99)00254-8. Am J Surg. 2000. PMID: 10737579

6

Transforming growth factor-alpha: a surrogate endpoint biomarker?

Beenken SW, Hockett R Jr, Grizzle W, Weiss HL, Pickens A, Perloff M, Malone WF, Bland KI. Beenken SW, et al. Among authors: weiss hl. J Am Coll Surg. 2002 Aug;195(2):149-58. doi: 10.1016/s1072-7515(02)01219-x. J Am Coll Surg. 2002. PMID: 12168960 Clinical Trial.

7

Effects of acute and chronic body weight gain reductions in the evaluation of agents for efficacy in mammary cancer prevention.

Rodríguez-Burford C, Lubet RA, Steele VE, Eto I, Bandy M, Juliana MM, Weiss HL, Grizzle WE, Kelloff GJ, Grubbs CJ. Rodríguez-Burford C, et al. Among authors: weiss hl. Oncol Rep. 2001 Mar-Apr;8(2):373-9. doi: 10.3892/or.8.2.373. Oncol Rep. 2001. PMID: 11182059

8

Phase specific analysis of herpes zoster associated pain data: a new statistical approach.

Arani RB, Soong SJ, Weiss HL, Wood MJ, Fiddian PA, Gnann JW, Whitley R. Arani RB, et al. Among authors: weiss hl. Stat Med. 2001 Aug 30;20(16):2429-39. doi: 10.1002/sim.851. Stat Med. 2001. PMID: 11512133

9

The efficacy of 9-cis-retinoic acid (aliretinoin) as a chemopreventive agent for cervical dysplasia: results of a randomized double-blind clinical trial.

Alvarez RD, Conner MG, Weiss H, Klug PM, Niwas S, Manne U, Bacus J, Kagan V, Sexton KC, Grubbs CJ, Eltoum IE, Grizzle WE. Alvarez RD, et al. Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):114-9. Cancer Epidemiol Biomarkers Prev. 2003. PMID: 12582020 Clinical Trial.

10

Longitudinal analysis of mammary cancer multiplicity in chemoprevention studies.

Weiss HL, Rodríguez-Burford C, Grubbs CJ, Grizzle WE. Weiss HL, et al. Anticancer Res. 2000 Jul-Aug;20(4):2281-7. Anticancer Res. 2000. PMID: 10953286

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

148 results

Search Page

Filters